argenx SE (ARGX) company profile
Close on Nov 13, 2026Market cap –P/E 49.1Yield –
About argenx
Biological Products, (No Diagnostic Substances), SIC 2836
The provided filing excerpt contains raw XBRL taxonomy identifiers and accounting data tags without any narrative corporate descriptions. Consequently, the excerpt does not disclose the company's business activities, main products, commercial services, operating segments, or customer base. The taxonomy references include equity items, share-based payment plans, and asset categories, but omit descriptive operational context.
The excerpt also provides no operational metrics, facility counts, geographic presence, or corporate headquarters location. While accounting tags reference Belgian tax regulations in the context of share awards, no geographic reach or headquarters details are disclosed in the text. Furthermore, the text does not state the founding year or an official website address.
Summary of the business section of argenx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- argenx SE
- Headquarters
- Zwijnaarde, Belgium
- Address
- Industriepark Zwijnaarde 7, Building C B-9052
- Phone
- (329) 310-3400
- Website
- argenx.com
- Employees
- 1,863, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- EY Accountants B.V., Eindhoven, the Netherlands
Stock & identifiers
- Ticker
- ARGX
- Exchange
- Nasdaq
- IPO date
- May 19, 2017
- Shares outstanding
- 62M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1697862
- CUSIP
- 04016X101
- ISIN
- US04016X1019
- FIGI
- BBG00GHB88X9
- Share class FIGI
- BBG00GHB88Y8
- LEI
- 7245009C5FZE6G9ODQ71
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
argenx's leadership is listed in its proxy statement (Form DEF 14A).
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 19, 2017
- Offer price
- $17.00
- Securities offered
- 5,865,000
- Gross proceeds
- $99.71M
- Exchange
- Nasdaq
- First trading day
- May 18, 2017
- First-day close
- $23.00+35.3%
- Lock-up ends (est.)
- Nov 14, 2017
“Per ADS Total Initial public offering price $ 17.00 $ 99,705,000 Underwriting discounts and commissions(1) $ 1.19 $ 6,979,350 Proceeds, before expenses, to argenx SE $ 15.81 $ 92,725,650 (1) We refer you to "Underwriting" beginning on page 292 of this prospectus for additional information regarding underwriting c”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“• Expansion to 1,863 full-time employees (as of December 31, 2025) to support further growth of our business,”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 6, 2026 | Tender offer | Third-party tender offer for the company's shares |
| May 19, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| May 16, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 21, 2017 | Name change | Name changed from argenx N.V to argenx SE |
See a number that looks wrong?